Mirum Pharmaceuticals, Inc. (MIRM) — Analyst outlook / Analyst consensus target is. Based on 18 analyst ratings, the consensus is bullish — 1 Strong Buy, 17 Buy.
The consensus price target is $116.70 (low: $95.00, high: $140.00), representing an upside of 20.4% from the current price $96.90.
Analysts estimate Earnings Per Share (EPS) of $-1.61 and revenue of $0.33B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-1.85 vs est $-1.61 (missed -14.7%). 2025: actual $-0.47 vs est $-0.25 (missed -90.8%). Analyst accuracy: 70%.
MIRM Stock — 12-Month Price Forecast
$116.70
▲ +20.43% Upside
Average Price Target
Based on 18 Wall Street analysts offering 12-month price targets for Mirum Pharmaceuticals, Inc., the average price target is $116.70, with a high forecast of $140.00, and a low forecast of $95.00.
The average price target represents a +20.43% change from the last price of $96.90.
Highest Price Target
$140.00
Average Price Target
$116.70
Lowest Price Target
$95.00
MIRM Analyst Ratings
Buy
Based on 18 analysts giving stock ratings to Mirum Pharmaceuticals, Inc. in the past 3 months
EPS Estimates — MIRM
70%
Analyst Accuracy
Fair
2 years compared
Actual vs Estimate
2024
Actual –$1.85
vs Est –$1.61
▼ 12.8% off
2025
Actual –$0.47
vs Est –$0.25
▼ 47.6% off
Profitability Outlook
Company has been making losses in all recent fiscal years. EPS is improving but still negative. Analysts expect losses to continue near-term.
Revenue Estimates — MIRM
99%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual $0.337B
vs Est $0.334B
▲ 0.7% off
2025
Actual $0.521B
vs Est $0.516B
▲ 1.1% off
Revenue Trend
Strong revenue growth over the period shown. Analysts forecast revenue contraction ahead.
